Caris Life Sciences, Inc. Common Stock (CAI)vsMerck & Company Inc (MRK)
CAI
Caris Life Sciences, Inc. Common Stock
$15.59
0.00%
HEALTHCARE · Cap: $4.66B
MRK
Merck & Company Inc
$130.40
-1.11%
HEALTHCARE · Cap: $307.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 7149% more annual revenue ($65.77B vs $907.29M). MRK leads profitability with a 13.6% profit margin vs 3.8%. MRK earns a higher WallStSmart Score of 50/100 (D+).
CAI
Hold44
out of 100
Grade: D
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CAI.
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$130.40
$49.17 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 78.8% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of 5.7% — below average capital efficiency
3.8% margin — thin
Operating margin of 2.4%
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CAI
The strongest argument for CAI centers on Revenue Growth. Revenue growth of 78.8% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CAI
The primary concerns for CAI are EPS Growth, Return on Equity, Profit Margin. Thin 3.8% margins leave little buffer for downturns.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CAI profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
CAI is growing revenue faster at 78.8% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 44/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caris Life Sciences, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The company is headquartered in San Francisco, California.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?